Novartis AG Total Non-Operating Income/Expense 2012-2026 | NVS

Novartis AG annual/quarterly total non-operating income/expense history and growth rate from 2012 to 2026. Total non-operating income/expense can be defined as the sum of all non-operating expenses for the given industry.
  • Novartis AG total non-operating income/expense for the quarter ending March 31, 2026 was $-0.396B, a 54.69% increase year-over-year.
  • Novartis AG total non-operating income/expense for the twelve months ending March 31, 2026 was $-1.432B, a 56.33% increase year-over-year.
  • Novartis AG annual total non-operating income/expense for 2025 was $-1.292B, a 42.92% increase from 2024.
  • Novartis AG annual total non-operating income/expense for 2024 was $-0.904B, a 39.94% increase from 2023.
  • Novartis AG annual total non-operating income/expense for 2023 was $-0.646B, a 15.99% decline from 2022.
Unlock Macrotrends Premium
40 years of data
Faster, ad-free pages
Unlimited data exports
Full-width charts
Novartis AG Annual Total Non-Operating Income/Expense
(Millions of US $)
2025 $-1,292
2024 $-904
2023 $-646
2022 $-769
2021 $14,448
2020 $-274
2019 $-146
2018 $5,692
2017 $370
2016 $-451
2015 $-843
2014 $1,183
2013 $-176
2012 $-271
2011 $-225
Novartis AG Quarterly Total Non-Operating Income/Expense
(Millions of US $)
2026-03-31 $-396
2025-12-31 $-398
2025-09-30 $-305
2025-06-30 $-333
2025-03-31 $-256
2024-12-31 $-245
2024-09-30 $-242
2024-06-30 $-173
2024-03-31 $-244
2023-12-31 $-205
2023-09-30 $-210
2023-06-30 $-133
2023-03-31 $-98
2022-12-31 $-161
2022-09-30 $-239
2022-06-30 $-186
2022-03-31 $-183
2021-12-31 $14,389
2021-09-30 $-3
2021-06-30 $27
2021-03-31 $35
2020-12-31 $-85
2020-09-30 $-2
2020-06-30 $-64
2020-03-31 $-123
2019-12-31 $-64
2019-09-30 $49
2019-06-30 $-29
2019-03-31 $-102
2018-12-31 $-29
2018-09-30 $12
2018-06-30 $5,740
2018-03-31 $-31
2017-12-31 $231
2017-09-30 $79
2017-06-30 $35
2017-03-31 $25
2016-12-31 $-377
2016-09-30 $5
2016-06-30 $20
2016-03-31 $-99
2015-12-31 $-546
2015-09-30 $-65
2015-06-30 $-125
2015-03-31 $-107
2014-12-31 $405
2014-09-30 $793
2014-06-30 $-37
2014-03-31 $22
2013-12-31 $-50
2013-09-30 $-70
2013-06-30 $1
2013-03-31 $-57
2012-12-31 $-54
2012-09-30 $-167
2012-06-30 $27
2012-03-31 $-77
2011-12-31 $-56
2011-09-30 $-43
2011-06-30 $-76
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $293.951B $54.532B
Novartis has one of the strongest and broadest portfolio of oncology drugs and generics. It continues to build depth in 5 core therapeutic areas Cardio-Renal, Immunology, Neuroscience, Oncology and Hematology, strength in technology platforms - Targeted Protein Degradation, Cell Therapy, Gene Therapy, Radioligand Therapy, and xRNA. Novartis efforts to strengthen its wide and deep oncology portfolio by developing breakthrough treatments. Cosentyx, Entresto, Kesimpta, Zolgensma, Kisqali and Leqvio. In March 2015, Novartis acquired certain oncology products and pipeline compounds from Glaxo. In exchange, it sold its non-influenza Vaccines business to Glaxo. Also, the company has spun off the Alcon business into a separate company. In January 2015, Novartis divested its Animal Health division to Lilly. In July 2015, the company divested its influenza vaccines business to CSL Limited. Novartis has also acquired The Medicines Company, adding Leqvio, to its portfolio. Novartis sold its investment in Roche.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $887.629B 38.81
Johnson & Johnson (JNJ) United States $574.358B 22.08
AbbVie (ABBV) United States $367.673B 20.79
Roche Holding AG (RHHBY) Switzerland $318.782B 0.00
Merck (MRK) United States $299.893B 13.54
Novo Nordisk (NVO) Denmark $167.527B 9.60
Pfizer (PFE) United States $153.074B 8.33
Sanofi (SNY) France $114.048B 10.56
Bayer (BAYRY) Germany $46.178B 8.70
Innoviva (INVA) United States $1.760B 5.88